RJ Hamster
Pre-Market Playbook – CPI Bounce — But The Line Is Drawn
— Read on premarket-playbook.beehiiv.com/p/pre-market-playbook-cpi-bounce-but-the-line-is-drawn
RJ Hamster
Dear Reader,
Valentine’s Day is tomorrow.
If you’re still looking for a way to show someone you care, don’t settle for a gift that will be forgotten by next week.
Flowers fade and chocolates disappear—but clarity, wisdom, and truth last a lifetime.
Instead of a last-minute “thing,” give them a gift that nourishes their mind every single day.
A gift subscription to The Epoch Times is more than just a gesture. It’s a way to say: “I value your mind. I respect your independence. And I want to give you a sanctuary of truth in a noisy world.”
Why this is the ultimate “win” for you and them:
• Zero Stress: You can set it up in seconds (no shipping delays!).
• Daily Value: Every time they open the web or the app, they’ll think of your thoughtful gift.
• Deep Connection: You’re sharing the values you both care about—integrity, tradition, and honest journalism.
Don’t be caught unprepared. Give a gift that will accompany your loved one throughout the entire year and offer something of real, lasting substance.
Give the Gift of Clarity – Ready in Minutes
Thank you for being a part of our mission to bring truth and tradition back to the world.
Wishing you a meaningful Valentine’s Day,
The Epoch Times Team
Copyright © 2026 The Epoch Times, All rights reserved. Our mailing address is: The Epoch Times. 129 West 29th Street, Fl 8, New York, NY 10001 | Contact Us
You are receiving this email because you subscribed to Epoch Special Offers email list.
RJ Hamster
View in your browser #MYTRILOGYLIFE Encanterra® Encanterra Leaderboard Feb 13, 2026 Featured Events 
Valentine’s Dinner-Dance: Taking Love Around the World on Valentine’s Day
Sat, Feb 14 
6:00 PM – 9:00 PM 
Other: Mallorca Events Center
Take your special someone on a culinary journey around the globe!
Join us for our annual Valentine’s Dinner-Dance on Saturday, February 14th beginning at 6:00pm, where unforgettable flavors, fine wine, and beautiful music come together for a magical evening.
Savor an array of international dishes – e…View Event
Mixology Demo | Chocolate Inspired CocktailsThu, Feb 19 2:00 PM – 3:30 PM Other: La Cocina
Mix, shake, stir! Trilogy loves Chocolate, and Bartender Kelli will be featuring some decadent cocktails that all include that ingredient we all love, chocolate. Join us on Thursday, February 19th at 2:00pm for this fun experience:
View Event
Concert | Evening at the Pops with the East Valley Pops OrchestraTue, Feb 24 6:30 PM – 8:30 PM Other: Mallorca Events Center
Henry Wadsworth Longfellow once said, ‘Music is the universal language of mankind.’ At Encanterra, we know our Members share a deep love for music. That’s why we carefully select top performers to entertain our Members, their families, and friends.
We are excited to present for the second year the East Valley Pops OrchestraView Event
Lionel Richie and Earth, Wind & Fire | SOLD OUT | WAITLIST STARTEDTue, Aug 11 6:00 PM – 11:30 PM Other: Offsite | Footprint Center
The current Pre-Sale is SOLD OUT. If you are interested in going please add yourself to the waitlist. We are working on securing more tickets.
Sing A Song! We are excited to announce Pre-Sale tickets to see legendary singer, songwriter and producer Lionel Richie and one of…View EventHouse Party at La Casa Thu, Feb 265:30 PM – 8:30 PMOther: Grand Living Room Pop-Up | Fish Fry Friday Fri, Feb 274:00 PM – 8:00 PMOther: Palma Kitchen & Tap Tribute Concert | RSO, A Tribute to REO Speedwagon Sat, Feb 285:00 PM – 6:30 PMOther: Algarve Spring Jazz Series featuring J. White Sun, Mar 12:00 PM – 5:00 PMOther: La Cocina / Amphitheater Floating Sound Bath Experience at Encanterra Thu, Mar 56:30 PM – 7:30 PMOther: Lap Pool Spring Artisan & Vendor Fair at The Algarve Sat, Mar 710:00 AM – 2:00 PMOther: The Algarve Lawn #MTL Magazine Release Party at the Fair Sat, Mar 710:00 AM – 2:00 PMOther: Algarve Lawn International Women’s Day: Celebrate Your Amazing Women Friends at Encanterra Sun, Mar 89:00 AM – 2:00 PMOther: Delivered Featured News 
#MTL Shop Valentine’s Day SalePosted: Feb 11, 2026
To celebrate Valentine’s Day, we’re sharing the love with a special sale in the #MTL Shop, running February 13th through 16th.
Treat your sweetheart (or yourself) with buy one, get one on all apparel and accessories. Pick your favorites and make this Valentine’s extra sweet!
View Post
#MTL ShopAlways Open. Always Original. Shop exclusive Trilogy gear. Shop Now
NewsKeep up to date with the latest news in your community 24 hours a day. Visit News
EventsLog in and find out about the latest events in your community. Visit Events
BulletinsShare your interests and Buy & Sell items with your neighbors. Visit BulletinsVisit MyTrilogyLife.com © 2026 All rights reserved. Use of the Website and the E-Newsletter is subject to website Terms of Use. Please review our Privacy Policy before providing any Personal Information. If you no longer wish to receive the E-Newsletter, please adjust your settings at the Website to unsubscribe
RJ Hamster
You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please unsubscribe here.
Prefer to view this content on our website? Click here.
Insiders don’t trade with perfect timing, and insider buying isn’t a guarantee that a stock will immediately rebound. But when executives and directors step in with meaningful purchases—especially after a pullback—it can be a useful signal. These buyers have a closer view of business conditions than the outside market: operating trends, pipeline catalysts, competitive dynamics, and internal expectations.
That matters even more when the buying shows two specific traits:
Below are three stocks where insider buying has recently stood out—one in sports betting, one in a high-volatility turnaround story, and one in blue-chip healthcare after a sharp earnings-driven selloff.
DraftKings has dealt with bouts of volatility tied to competitive intensity, promotional spending, and shifts in sentiment around the long-term economics of online sports betting. Recently, after a pullback tied to renewed competitive concerns, two insiders treated the weakness as an opportunity—and the combined size of their purchases is notable.
Together, that’s approximately $1.06 million in insider buying—an amount that tends to get attention because it implies conviction, not just optics.
DKNG last traded around $27.03.
In a competitive consumer category like online sports betting, sentiment can swing sharply on headlines (tax changes, promos, state-level dynamics, rival pricing). Insider purchases after a selloff can suggest management and directors believe the market has over-discounted near-term noise relative to longer-term value.
Equiscreen
Viruses are wreaking havoc across the globe—this flu season has already caused millions of infections, RSV is killing children, and measles cases are forcing public health warnings.
Amid this mounting crisis, NanoViricides (NYSE: NNVC) is quietly developing NV-387, a broad-spectrum antiviral that has proven in animal studies to cure RSV, outperform Tamiflu and Xofluza against influenza, and target coronaviruses, smallpox, and MPox.
NV-387 completed Phase I with no adverse events and is now cleared to start a Phase II Mpox trial in the Democratic Republic of Congo, a major milestone that puts NNVC in the spotlight!
Investors should be paying attention now: NNVC isn’t just another biotech—it’s a potential game-changer in antiviral therapy, creating the first truly broad-spectrum treatment that viruses cannot escape.
With regulatory approvals in place and a platform that could target over 90% of human pathogenic viruses, NNVC represents a rare opportunity in the highly watched biotech space.
See why NNVC is the breakout biotech every investor needs to have on their radar
GameStop remains a special situation: high volatility, heavy narrative component, and a market that tends to react strongly to insider activity and positioning.
Recent insider buying has been substantial:
GME last traded around $24.94.
Large insider purchases can carry extra weight in a story stock because they shift the framing from “narrative” to “alignment.” When a CEO increases exposure materially, it signals a willingness to tie personal outcomes to the stock’s future.
There’s also external interest worth noting. Business Insider reported that Michael Burry disclosed buying GameStop again and framed it as a fundamentals-driven, asymmetric opportunity—not a meme-stock squeeze bet.
GameStop is not a traditional “insider buy = easy rebound” setup. It can move violently in both directions, and the market’s reaction often depends on sentiment, liquidity, and the broader risk environment. Insider buying can be a signal, but it doesn’t remove the need for disciplined risk controls.
Trading Tips
Wall Street’s betting big on these $5 stocks (100% upside targets)
Most investors won’t touch stocks under $10.
They think cheap means junk. Meanwhile, institutional analysts are quietly slapping “Strong Buy” ratings on three companies trading around $5 each.
The math is simple: When a $5 stock hits its analyst target of $11, you’re looking at 100%+ gains. When a $500 stock doubles, you need it to hit $1,000. Which seems more achievable?
Right now, three overlooked companies under $10 are getting aggressive price targets from major Wall Street firms. These aren’t penny stock pump-and-dumps. These are real businesses
Click here to get your free copy of this report >
(By clicking this link you agree to receive emails from Trading Tips and our affiliates. You can opt out at any time. – Privacy Policy)
Abbott is the “anti-meme” entry on this list: a global healthcare franchise that sold off hard on earnings, creating a different kind of setup—one built around credibility, stability, and the signal value of a CEO stepping in after a major gap down.
Barron’s reported Abbott shares fell sharply following results, and CEO Robert Ford bought 18,800 shares (~$2 million) at around $107.13.
Yahoo Finance also summarized the Form 4 details and highlighted the purchase price around $107.13.
ABT last traded around $112.66.
CEO buys after an earnings-driven collapse tend to be interpreted as a “confidence signal,” particularly for large-cap companies where insider purchases are less frequent and usually more deliberate. This type of buy often aims to reassure investors that the selloff was an overreaction to a fixable issue, not a permanent impairment.
In this case, Barron’s noted the miss was tied largely to weakness in the nutrition segment, while Ford expressed confidence in accelerating growth into 2026.
EnergyX
This Critical Mineral’s Up 122% in the Last 12 Months.
No, not gold. It’s lithium, which just hit two-year highs. What’s spurring this “white gold” rush? Critical to everything from AI to robotics to EVs, lithium demand will grow 5X by 2040. As Elon Musk put it, “It’s a license to print money.” Enter EnergyX. Their patented tech can recover 3X as much lithium as traditional methods. That’s why General Motors led a $50M investment round. Now you can join too.
Join 40k+ people as an EnergyX investor before their share price increases after 2/26.
Are there any other stocks with notable recent insider buying that you’re keeping an eye on? What other sectors of the market are you focusing on in 2026? Hit “reply” to this email and let us know your thoughts!
We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security.
We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of NanoViricides, Inc. (NYSE American: NNVC). The compensation consists of up to $6,500 and was received/will be received from Interactive Offers.
This communication should not be considered as an endorsement of the securities of adviser NanoViricides, Inc. (NYSE American: NNVC) and we are not responsible for any errors or omissions in any information provided about the securities of NanoViricides, Inc. (NYSE American: NNVC) and Interactive Offers.
We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions.
This disclosure is made as of 02/13/2026.
DISCLOSURE: EnergyX’s Regulation A offering has been qualified by the SEC. Before investing, carefully review the offering circular, including the risk factors. The offering circular is available at invest.energyx.com
Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431
Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You’re receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices.
Behind the Markets
RJ Hamster
A message from our sponsor
Manes blowing in the breeze. Green as far as the eye can see. All’s quiet on the Mongolian plains, save for the thunder of galloping hooves.
Strength. Free spirit. Loyalty. Endurance. This is the Year of the Horse.
And what better way to celebrate than at Shen Yun, where ancient legends come to life with breathtaking athleticism.
But don’t let this opportunity race past you. Reserve your seats today.
Tucson 2/28–3/1
Phoenix 3/5–8BOOK TICKETS Use Code: Year2026
Waive ticketing fees. Limited availability. Call: 800-880-0188 Not your city? Find all cities here“Soulful. Chinese culture
in its fullest flower.
An explosion of color and sound” —Charlotte Observer “A joyous celebration. Spectacular” —Theatre Scene
Please take a moment to read the special message from our advertising sponsor. Our sponsors help us keep our news service independent, though we do not necessarily endorse this message. Want us to stop emailing you? Manage your email preferences here.The Epoch Times. 229 W. 28 St. Fl. 7 New York,NY 10001
All photos and images © 2026 Shen Yun Performing Arts. All Rights Reserved.
RJ Hamster
AD FinanceBuzz
Gas Pump Footage: Ultimate Card Secret
A doctor just owned Washington liberals with this claim about President Trump’s brain:
“There’s just no question he shows clear signs of…” >>View the evidence here<<
This ad is sent on behalf of NewMarket Health Publishing, LLC. P.O. Box 913, Frederick, MD 21705, USA. If you would like to unsubscribe from receiving offers from NewMarket Health Publishing, LLC, please click here.
Trending Now
AD Behind the Markets
AD NewMarket Health Publishing
AD Awesomely
Editorial Note: This investment opportunity has been carefully reviewed by our editorial team. We recommend that all investors conduct their own due diligence and consult with financial advisors before making investment decisions.
This newsletter was sent to pahovis@aol.com. Questions or feedback? Contact our support team at support@welthok.com
Privacy Policy | Terms and Conditions
Published by Prestige Publishing LLC
200 Continental Dr Suite 401, Newark, DE 19713
RJ Hamster
The countdown to expiration week has begun…
Things are going to look a little different this time around.
Recently, investors have been focused on the holiday rush and the turn of the calendar. Now, attention has shifted. The market is reacting (sometimes violently) to new information.
The first jobs report for 2026 is out, consumer spending from December came in flatter than expected, and earnings season continues to deliver surprises that force investors to reassess positioning quickly.
And while the Dow recently notched a new all-time high, that move followed a broader market selloff the prior week, as concerns swirled around software and mega-cap tech stocks.
In environments like this, there’s too much opportunity to ignore… but exposure becomes far less forgiving.
If the idea of targeting meaningful gains without staying overexposed to risk sounds appealing, you’ll want to read on.
Let me explain.
In just a few short days, on the evening of Sunday, February 15th, I’ll release six expiration week trades, each one designed to capitalize on the most compressed part of the monthly options cycle.
Each of these six trades will target 200% gains (or more) in five days or less.
That’s right… all positions are structured to close by Friday, February 20th.
That’s the advantage of trading during this window. You’re not waiting weeks for a thesis to play out. You’re operating inside a defined, high-energy stretch where small stock moves can translate into outsized option gains.
These trades are delivered through a long-standing favorite here at Schaeffer’s called Expiration Week Countdown.
Here’s just a sampling of recent triple-digit wins, each one closed out within five trading days:
As you can see, sometimes it doesn’t take the full five days. In January, Chubb took the full trading week to score its triple-digit return, but Roblox closed out on Wednesday – just two trading sessions!
This Is Your Opportunity to Tighten Your Trading Window
We’ll release our next batch of six expiration week trades at 7 p.m. ET this Sunday, February 15th, and I’d love nothing more than to include you in that email.
You’ll have the opportunity to target meaningful gains while other investors are still reacting… and you’ll be out of all positions by Friday, February 20th, at the latest.
And the great thing about this amazing strategy is that we do it every month. Expiration Week Countdown is a monthly trade delivery system, giving you repeated opportunities to apply the same disciplined approach – March, April, and beyond.
Now, if you sign up today, you’ll actually see how this strategy works in an even more compressed window. Normally, you’ll enter your trades on Monday after they arrived in your inbox.
But because the market is closed on Monday, February 16th, you’ll actually place this month’s trades on Tuesday, February 17th.
Effectively, that means you’ll see February Expiration Week Countdown trades play out in four days instead of five.
But it’s important that we target expiration week for this strategy to work.
You see, options traders gravitate toward expiration week for a simple reason: when contracts have five days or less until expiration, moves of just 7% to 15% in the underlying stock can produce triple-digit option gains.
You don’t need massive stock rallies. You need timing and a defined plan.
Plus, because these trades are held for just a few days, you’re not tied to long-term market direction or drawn-out uncertainty.
And not only is trading Expiration Week Countdown quick… but it’s super easy, too.
Stop Trying to Time the Market – Join Now!
A full year of Expiration Week Countdown typically retails for $1,747. That reflects the scope of the service—six short-term option opportunities every month, each built to target 200% gains or more in five days or less.
This price is rarely discounted…
But you’re in luck today, because I’m making 50 spots available with this amazing opportunity.
First of all, you won’t pay anywhere near $1,747 to get into Expiration Week Countdown.
Instead, you’ll pay just $95. That’s HUGE savings off the normal annual cost…
And there’s one more thing…
YOUR EXCLUSIVE LONG WEEKEND BONUS
As part of this offer, new subscribers will also receive an additional 12 months of Expiration Week Countdown at no extra cost.
That means your $95 today covers a full 24 months of trades — two complete years, with six expiration week opportunities delivered every month.
It’s a straightforward way to lock in extended access to a strategy designed for short-duration trades, compressed timeframes, and repeatable execution—at a cost well below what most subscribers typically pay for a single year.
But please don’t forget… this offer is only available to the first 50 to respond. It will end as soon as the 50th spot is claimed or at midnight on Saturday, whichever comes first.
I’d like nothing more than to help you bank some serious cash during February expiration week.
So, don’t delay. Join Expiration Week Countdown right now and get ready for the fastest profits you’ve seen so far this year.
Sincerely,
Bernie Schaeffer
Founder & CEO
Schaeffer’s Investment Research
🌐 http://www.schaeffersresearch.com
📞1-800-448-2080
International 1-513-589-3800
Update your email preferences or unsubscribe here
© 2026 Schaeffer’s Investment Research
5151 Pfeiffer Road, Suite 450
Cincinnati, Ohio 45242, United StatesTerms of Service
RJ Hamster
EARN WHILE YOU LEARN! JOIN OUR FREE LIVE TRADING SESSION!
Hello Peter Anthony Hovis,
AI Triggers Bloodbath in Logistics and Real Estate
Yesterday’s most dramatic story unfolded in the business of transporting goods.
Namely, the trucking and logistics industry found itself in the crosshairs of a “SaaS-style” apocalypse. The catalyst was a whitepaper from Algorhythm Holdings, a company that recently pivoted from selling in-car karaoke machines to developing freight-optimization AI.
Their SemiCab platform promised a future where “empty miles,” which are one out of every three miles trucks currently drive without cargo, are virtually eliminated.
(Source: SemiCab)
The results were immediate and unforgiving.
Logistics powerhouses C.H. Robinson and RXO saw their valuations crater, each dropping more than 20% in a single session.
The carnage didn’t stop at the loading dock.
The panic in commercial real estate stocks continued for its second straight day, and the sector suffered its deepest losses since the 2020 pandemic. Investors are increasingly haunted by the “agentic AI” threat, where tools like Anthropic’s “Claude Cowork” can audit thousands of leases in seconds.
It may threaten the high-fee, labor-intensive models of firms like CBRE and Jones Lang LaSalle. CBRE’s stock tumbled 12.8%, a move so sharp it echoed the darkest days of the 2008 financial crisis.
The mood was further darkened by a viral essay from OtherSide AI CEO Matt Shumer, who warned that the “white-collar gutting” from AI would be more impactful than Covid.
OtherSide AI CEO Matt Shumer (Photo: AI Speakers Agency)
This sentiment was bolstered by Elon Musk’s recent podcast appearance, where he said AI-first corporations would outperform the current corporation structure filled with people.
He used an example of the past days, when skyscrapers were filled with humans doing calculations. Not anymore. They are replaced by a smaller number of humans using laptops that run calculations on spreadsheets.
The AI fear is spreading across sectors, and not a single sector is safe from it. While some, like AWS CEO Matt Garman, argue the fear is “overblown,” the market’s current “sell first, ask questions later” mentality suggests that investors are extremely anxious about how disruptive AI can be to incumbents.
For now, the fear is more powerful than the optimism surrounding AI. The market has lost its momentum after its strong recovery from the steep software sell-off, and investors are waiting for the next major catalyst to get the bull market back on the track.
Why 908 Devices Is Currently One of Wall Street’s Most Liquid Small-Caps
Today’s Stock Pick: 908 Devices Inc. (MASS)
908 Devices is the company that builds handheld devices that can detect fentanyl in seconds.
How it works is simple.
Point a device the size of a handheld radio at a suspicious substance, wait a few moments, and sophisticated mass spectrometry identifies exactly what you’re dealing with.
(Source: 908 Devices)
For law enforcement officers, customs agents, and first responders facing the deadliest drug crisis in American history, these devices aren’t just convenient. They’re potentially lifesaving.
(Source: 908 Devices)
Wall Street hasn’t fully embraced the stock yet, with the market cap sitting at just $232 million. 908 Devices presents an intriguing opportunity at the intersection of three powerful trends: the opioid epidemic, rising defense spending, and border security concerns.
The Strategic Pivot That Changes Everything: In March 2025, 908 Devices made a defining move. Management sold its entire desktop bioprocessing product line to Repligen Corporation for $70 million cash, nearly doubling the balance sheet overnight.
The desktop products served pharmaceutical and biotech companies, generating $13.2 million in 2024. But they represented a distraction from what CEO Kevin Knopp saw as the company’s real future:
Handheld chemical detection devices for frontline health, safety, and defense applications.
By divesting these assets, 908 Devices shed a third of its workforce, eliminated $20 million in annual operating losses, and sharpened its focus on the faster-growing handheld market.
The company emerged with ~$110 million in cash and essentially zero debt.
That’s right — its cash position is 47% of its total market cap.
(Source: 908 Devices)
More importantly, it positioned itself squarely in front of secular tailwinds that show no signs of slowing.
Three Crises Creating One Market Opportunity: The opioid crisis has evolved into a full-blown national emergency. Over 100,000 Americans died from drug overdoses in 2023, the leading cause of injury deaths, surpassing automobile accidents. The federal government declared a nationwide public health emergency in June 2024.
Traditional drug testing strips can’t keep pace. What law enforcement needs is adaptable technology that can identify unknown substances quickly and accurately.
Beyond drugs, toxic industrial materials pose growing threats. Consumer products in California emit over 5,000 tons of hazardous volatile organic compounds annually. Cancer accounts for 72% of firefighter line-of-duty deaths in the United States. First responders need better detection equipment, yet most operate with outdated technology from the early 2010s.
Rising global tensions add a third dimension. In 2024, 80 countries held national elections. President Trump designated drug cartels as “Foreign Terrorists” in January 2025, elevating border security to a national priority. The Organization for the Prohibition of Chemical Weapons reports increased risks of chemical weapons use. These trends are creating what industry analysts estimate to be a 15,000-unit equipment modernization opportunity across customs agencies, law enforcement departments, and military units worldwide.
(Source: 908 Devices)
908 Devices has assembled something its larger competitors don’t offer: A comprehensive suite of handheld devices covering the full spectrum of chemical analysis needs.
The MX908 flagship product is the only handheld mass spectrometer on the market, analyzing solids, liquids, vapors, and aerosols. Over 2,800 MX devices have been fielded globally.
In July 2025, the company launched VipIR, a 3-in-1 handheld analyzer combining Raman and Fourier-transform infrared spectroscopy. Its proprietary “Smart Spectral Processing” algorithms integrate data from both technologies to analyze complex or mixed substances from one sample. The library contains over 39,000 chemical spectra.
(Source: 908 Devices)
The company has also built connected services that competitors ignore. The Team Leader app provides 24/7/365 expert support, fleet management, usage tracking, and AI-powered guidance.
(Source: 908 Devices)
For enterprise customers managing hundreds of devices, these software tools transform individual instruments into an integrated detection network.
The Path to Profitability Is Clear: For years, 908 Devices burned cash trying to be everything to everyone. In 2024, the company generated $47.7 million in revenue from continuing operations but recorded an adjusted EBITDA loss of $29.7 million.
The transformation changes the math entirely.
Management expects adjusted EBITDA positivity by Q4 2025 and full-year cash flow positivity in 2026.
If accomplished, it may be a game-changer for its stock price.
(Source: 908 Devices)
Recurring revenue reached $9.1 million in the first half of 2025, representing 37% of total revenue and growing 31% year-over-year. As the installed base grows, recurring revenue becomes increasingly predictable and profitable.
With $119 million in cash and zero debt, 908 Devices has the runway to execute without raising capital or diluting shareholders.
Future Guidance: Management guides for $54 million to $56 million in revenue for 2025, representing 13% to 17% growth.
Looking ahead to 2026, management expects to return to over 20% growth as the three catalysts kick in.
If the company hits that growth rate and achieves projected gross margins in the mid-to-high 50% range, the operating leverage becomes compelling.
Bottom line: For growth investors comfortable with small-cap volatility, 908 Devices offers an asymmetric opportunity. If management executes and the catalysts play out, the stock could do well. The downside is cushioned by $110 million in cash, representing over 40% of the current market cap.
EARN WHILE YOU LEARN! JOIN OUR FREE LIVE TRADING SESSION!
© All Rights Reserved, Trade Alliance
RJ Hamster
EARN WHILE YOU LEARN! JOIN OUR FREE LIVE TRADING SESSION!
Hello Peter Anthony Hovis,
AI Triggers Bloodbath in Logistics and Real Estate
Yesterday’s most dramatic story unfolded in the business of transporting goods.
Namely, the trucking and logistics industry found itself in the crosshairs of a “SaaS-style” apocalypse. The catalyst was a whitepaper from Algorhythm Holdings, a company that recently pivoted from selling in-car karaoke machines to developing freight-optimization AI.
Their SemiCab platform promised a future where “empty miles,” which are one out of every three miles trucks currently drive without cargo, are virtually eliminated.
(Source: SemiCab)
The results were immediate and unforgiving.
Logistics powerhouses C.H. Robinson and RXO saw their valuations crater, each dropping more than 20% in a single session.
The carnage didn’t stop at the loading dock.
The panic in commercial real estate stocks continued for its second straight day, and the sector suffered its deepest losses since the 2020 pandemic. Investors are increasingly haunted by the “agentic AI” threat, where tools like Anthropic’s “Claude Cowork” can audit thousands of leases in seconds.
It may threaten the high-fee, labor-intensive models of firms like CBRE and Jones Lang LaSalle. CBRE’s stock tumbled 12.8%, a move so sharp it echoed the darkest days of the 2008 financial crisis.
The mood was further darkened by a viral essay from OtherSide AI CEO Matt Shumer, who warned that the “white-collar gutting” from AI would be more impactful than Covid.
OtherSide AI CEO Matt Shumer (Photo: AI Speakers Agency)
This sentiment was bolstered by Elon Musk’s recent podcast appearance, where he said AI-first corporations would outperform the current corporation structure filled with people.
He used an example of the past days, when skyscrapers were filled with humans doing calculations. Not anymore. They are replaced by a smaller number of humans using laptops that run calculations on spreadsheets.
The AI fear is spreading across sectors, and not a single sector is safe from it. While some, like AWS CEO Matt Garman, argue the fear is “overblown,” the market’s current “sell first, ask questions later” mentality suggests that investors are extremely anxious about how disruptive AI can be to incumbents.
For now, the fear is more powerful than the optimism surrounding AI. The market has lost its momentum after its strong recovery from the steep software sell-off, and investors are waiting for the next major catalyst to get the bull market back on the track.
Why 908 Devices Is Currently One of Wall Street’s Most Liquid Small-Caps
Today’s Stock Pick: 908 Devices Inc. (MASS)
908 Devices is the company that builds handheld devices that can detect fentanyl in seconds.
How it works is simple.
Point a device the size of a handheld radio at a suspicious substance, wait a few moments, and sophisticated mass spectrometry identifies exactly what you’re dealing with.
(Source: 908 Devices)
For law enforcement officers, customs agents, and first responders facing the deadliest drug crisis in American history, these devices aren’t just convenient. They’re potentially lifesaving.
(Source: 908 Devices)
Wall Street hasn’t fully embraced the stock yet, with the market cap sitting at just $232 million. 908 Devices presents an intriguing opportunity at the intersection of three powerful trends: the opioid epidemic, rising defense spending, and border security concerns.
The Strategic Pivot That Changes Everything: In March 2025, 908 Devices made a defining move. Management sold its entire desktop bioprocessing product line to Repligen Corporation for $70 million cash, nearly doubling the balance sheet overnight.
The desktop products served pharmaceutical and biotech companies, generating $13.2 million in 2024. But they represented a distraction from what CEO Kevin Knopp saw as the company’s real future:
Handheld chemical detection devices for frontline health, safety, and defense applications.
By divesting these assets, 908 Devices shed a third of its workforce, eliminated $20 million in annual operating losses, and sharpened its focus on the faster-growing handheld market.
The company emerged with ~$110 million in cash and essentially zero debt.
That’s right — its cash position is 47% of its total market cap.
(Source: 908 Devices)
More importantly, it positioned itself squarely in front of secular tailwinds that show no signs of slowing.
Three Crises Creating One Market Opportunity: The opioid crisis has evolved into a full-blown national emergency. Over 100,000 Americans died from drug overdoses in 2023, the leading cause of injury deaths, surpassing automobile accidents. The federal government declared a nationwide public health emergency in June 2024.
Traditional drug testing strips can’t keep pace. What law enforcement needs is adaptable technology that can identify unknown substances quickly and accurately.
Beyond drugs, toxic industrial materials pose growing threats. Consumer products in California emit over 5,000 tons of hazardous volatile organic compounds annually. Cancer accounts for 72% of firefighter line-of-duty deaths in the United States. First responders need better detection equipment, yet most operate with outdated technology from the early 2010s.
Rising global tensions add a third dimension. In 2024, 80 countries held national elections. President Trump designated drug cartels as “Foreign Terrorists” in January 2025, elevating border security to a national priority. The Organization for the Prohibition of Chemical Weapons reports increased risks of chemical weapons use. These trends are creating what industry analysts estimate to be a 15,000-unit equipment modernization opportunity across customs agencies, law enforcement departments, and military units worldwide.
(Source: 908 Devices)
908 Devices has assembled something its larger competitors don’t offer: A comprehensive suite of handheld devices covering the full spectrum of chemical analysis needs.
The MX908 flagship product is the only handheld mass spectrometer on the market, analyzing solids, liquids, vapors, and aerosols. Over 2,800 MX devices have been fielded globally.
In July 2025, the company launched VipIR, a 3-in-1 handheld analyzer combining Raman and Fourier-transform infrared spectroscopy. Its proprietary “Smart Spectral Processing” algorithms integrate data from both technologies to analyze complex or mixed substances from one sample. The library contains over 39,000 chemical spectra.
(Source: 908 Devices)
The company has also built connected services that competitors ignore. The Team Leader app provides 24/7/365 expert support, fleet management, usage tracking, and AI-powered guidance.
(Source: 908 Devices)
For enterprise customers managing hundreds of devices, these software tools transform individual instruments into an integrated detection network.
The Path to Profitability Is Clear: For years, 908 Devices burned cash trying to be everything to everyone. In 2024, the company generated $47.7 million in revenue from continuing operations but recorded an adjusted EBITDA loss of $29.7 million.
The transformation changes the math entirely.
Management expects adjusted EBITDA positivity by Q4 2025 and full-year cash flow positivity in 2026.
If accomplished, it may be a game-changer for its stock price.
(Source: 908 Devices)
Recurring revenue reached $9.1 million in the first half of 2025, representing 37% of total revenue and growing 31% year-over-year. As the installed base grows, recurring revenue becomes increasingly predictable and profitable.
With $119 million in cash and zero debt, 908 Devices has the runway to execute without raising capital or diluting shareholders.
Future Guidance: Management guides for $54 million to $56 million in revenue for 2025, representing 13% to 17% growth.
Looking ahead to 2026, management expects to return to over 20% growth as the three catalysts kick in.
If the company hits that growth rate and achieves projected gross margins in the mid-to-high 50% range, the operating leverage becomes compelling.
Bottom line: For growth investors comfortable with small-cap volatility, 908 Devices offers an asymmetric opportunity. If management executes and the catalysts play out, the stock could do well. The downside is cushioned by $110 million in cash, representing over 40% of the current market cap.
EARN WHILE YOU LEARN! JOIN OUR FREE LIVE TRADING SESSION!
© All Rights Reserved, Trade Alliance
RJ Hamster
If you missed Bitcoin in 2011, Tesla in 2012, or NVIDIA in 2016, you know the sting of regret…
Now the master trader Jeff Clark has uncovered a new opportunity. He calls it “Crossfire” — and it could hand you gains of as much as 1,285% in as little as two days. Don’t let this become another “what-if” moment.Watch his free briefing now
To ensure that you continue to receive marketing emails from TradeSmith, please add info@exct.tradesmith.com to your address book.
If you no longer want to receive marketing emails from TradeSmith, please click here to unsubscribe.
If you have any questions, please don’t hesitate to contact Customer Service at support@tradesmith.com or by calling 1-866-385-2076.
© 2026 TradeSmith, LLC. All Rights Reserved. 1125 N. Charles Street, Baltimore, MD 21201
Terms of Use | Privacy Policy | Unsubscribe
If you missed Bitcoin in 2011, Tesla in 2012, or NVIDIA in 2016, you know the sting of regret…
Now the master trader Jeff Clark has uncovered a new opportunity. He calls it “Crossfire” — and it could hand you gains of as much as 1,285% in as little as two days. Don’t let this become another “what-if” moment.Watch his free briefing now
To ensure that you continue to receive marketing emails from TradeSmith, please add info@exct.tradesmith.com to your address book.
If you no longer want to receive marketing emails from TradeSmith, please click here to unsubscribe.
If you have any questions, please don’t hesitate to contact Customer Service at support@tradesmith.com or by calling 1-866-385-2076.
© 2026 TradeSmith, LLC. All Rights Reserved. 1125 N. Charles Street, Baltimore, MD 21201